It is intended for the treatment of deep wrinkles, laxity and significant tissue defects.

WOW EFFECT! Thanks to the combination of PDLLA polylactic acid with HA hyaluronic acid, we obtain an effect that is visible immediately after the treatment.

The filling is maintained until the production of new collagen, elastin, by polylactic acid begins to dominate.

  • Lactic acid (PLA) was originally synthesized from α-hydroxy acids by French chemists in 1954. This polymer is safely used in resorbable suture materials, plates and screws in orthopedic, neurological and craniofacial surgery. PLA creates chiral molecules (cthe starting molecule and its mirror image are not identical, chiral objects cannot be superimposed, they are a property of natural compounds) poly-L type (PLLA), poly-D type, poly-D, L-lactic acid (PDLLA) and  meso-PLA. Only PLLA and PDLLA have been extensively researched with promising results.

    In 1999, PLLA for injection was approved for use in Europe (New-Fill; Biotech Industry SA, Luksemburg).Initially, the product was registered as “wrinkle filler”. In 2004, it was approved in Europe to correct large volume losses in patients suffering from lipoatrophy.

    On August 3, 2004, the United States Food and Drug Administration (FDA) approved Sculptra ™ (Dermik Laboratories, Berwyn, PA, USA) to correct volume losses resulting from facial lipoatrophy in HIV-infected patients. In 2009, this approval was extended to cosmetic / aesthetic medicine applications.

    Plastic and Aesthetic Research

    Efficacy and safety of poly-D,L-lactic acid microspheres as subdermal fillers in animals

    Chuan-Yuan Lin1, Jui-Yu Lin1, Dae-Yeol Yang2, Seong-Ho Lee3, Jeoung-Yong Kim4, Miyeon Kang5  – Published: 25 Jul 2019

Poly-D,L-lactic acid (PDLLA) is a synthetic, biocompatible, biodegradable polymer.

In soft tissue augmentation, the size and chemical properties of the PDLLA microparticle are critical to its ability to initiate a subclinical inflammatory response,
which stimulates collagen deposition in the extracellular matrix.

The resulting facial volume restoration is controlled, predictable and long-lasting.

The unique physicochemical biostimulating properties of PDLLA set it apart from other available treatments and are the basis of the required unique treatment methodology for optimal results.

PDLLA is currently the most durable of all approved, certified biodegradable products.

Full correction still occurs in 80% of patients after 24 months. PLA (Polylactic Acid) is known as a collagen stimulator and offers unique and effective ways to deal with tissue defects for a natural and lasting effect.

Plastic and Aesthetic Research

“Efficacy and safety of poly-D,L-lactic acid microspheres as subdermal fillers in animals”

Chuan-Yuan Lin1, Jui-Yu Lin1, Dae-Yeol Yang2, Seong-Ho Lee3, Jeoung-Yong Kim4, Miyeon Kang5 – Published: 25 Jul 2019

The injection of polylactic acid causes a biological reaction in the subcutaneous tissue, similar, but less inflammatory to that seen during wound healing and suturing. There is a natural transition from acute to low-grade chronic inflammation.

  1. Intentional inflammatory reaction around a foreign body
  2. Fibroplasia (growth of fibrous connective tissue) in the skin,
  3. Collagenogenesis stimulated by lactates released into the tissues and the slow degradation of PDLLA microparticles are those factors that to varying degrees contribute to the long-term clinical effect that persists after the procedure.

The foreign body inflammatory response leads to microparticle encapsulation followed by fibroplasia and the resulting deposition of type I collagen in the extracellular space.


  1. Tissue response to PDLLA from acute inflammation to declining inflammatory response.
  2. Protein adsorption occurs immediately after injection followed by infiltration by neutrophils and then macrophages.
  3. PDLLA degradation, and collagen accumulation over time.
  4. After 6 months, the number of macrophages and fibrocytes decreases (Fibrocyte – a connective tissue cell present as a reduced form of fibroblast with a lower metabolic efficiency – a senile cell, used up)
  5. Collagen production continues to increase and inflammation returns to baseline levels.

LENISNA particles are large enough to avoid phagocytosis via macrophages in the skin,  or penetrate the walls of the capillaries, but at the same time they are small enough to be easily injected with a needle without blocking it. They do not cause lumps under the skin due to their round and porous shape.

Injectable fillers offer simple and minimally invasive techniques to expand tissue. Ideal materials for such treatments must be easy to inject, non-migratory, volume stable, biodegradable and biocompatible. Currently, many types of tissue fillers are used in routine clinical practice for cosmetic and medical indications. These tissue fillers can be classified as temporary, semi-permanent, or permanent, depending on the duration of injection of the product into the tissues. These fillers are also classified according to their composition, and the following has been studied: collagen (bovine, porcine and human), hyaluronic acid (HA), polylactic acid PLA, calcium hydroxylapatite (CaHA), polymethyl methacrylate, polyacrylamide and autologous fat cells. Among these fillers, CaHA and PLA (Polylactic Acid) are known as collagen stimulants and offer unique and effective ways to deal with tissue defects for a natural and lasting effect.

Plastic and Aesthetic Research

Efficacy and safety of poly-D,L-lactic acid microspheres as subdermal fillers in animals

Chuan-Yuan Lin1, Jui-Yu Lin1, Dae-Yeol Yang2, Seong-Ho Lee3, Jeoung-Yong Kim4, Miyeon Kang5  – Published: 25 Jul 2019

The treatment should be repeated 2/3 times at intervals of 6 to 8 weeks. Duration of the procedure from the last visit exceeds 24 months.

Descriptions of the beneficial effects of polylactic acid in patients for up to 40 months can be found in the literature. The percentage of satisfied patients exceeds 90%.

The poly L lactic acid particles have the structure of broken glass, and the poly D, L lactic acid microparticles are round, porous with a mesh structure. This unique structure of molecules allows it to connect with non-cross-linked hyaluronic acid, which makes this preparation unique.

  • Patent : No. 10-1481441 Manufacturing method of polymeric microparticles having network structure
  • Patent : No. 10-1725279 A process for the preparation of polylactic acid microparticles by a spray method
  1. A comparison between hyaluronic acid and polylactic acid filler injections for temporary penile augmentation in patients with small penis syndrome. Authors: Dae Yul Yang, MD Phd; Hyun Cheol Jeong , MD,; Sun Tae Ahn, MD, PhD; Woong Jin Bae, MD, Phd; Du Geon Moon, MD, PhD; Sae Woong Kim, MD, PhD, and Won Ki Lee, MD, PhD
  2. Biostymulatory effects of polydioxanonoe, PDLLA and polycaprolactone fillers in mouse model. Authors Tae-Rin Kwon PhD, Sung Won Han MS; In Kwon Yeo MD, Jong Hwan Kim MS, Jae Min Kim MD, Ji-Yeon Hong MD, Byung-Chul Lee MS, Sung-Eun Lee MS, Ho Sang Moon PhD, Han Jin Kwon PhD, Beom Joon Kim MD
  3. Efficacy and safety of PDLLA microsperes as subdermal fillers in animals. Chuan-Yuan Lin, Jui-Yu Lin, Dae-Yeol Yang, Seong-Ho Lee, Jeoung-Yong Kim, Miyeon Kang
  4. PDLLA membranes for bone regeneration. Marco Annunziata, DDS, PhD; Livia Nastri, DDS, PhD; Andrea Borgonovo, MD, DMD; Marco Benigni, DDS and Pier Paolo Poli DDS.
  5. Development and characterization of polymeric microparticle of PDLLA loaded with holmium acetylacetonate. Mariangela de Burgos M. de Azevedo, Vitor H. S. de Melo, Carlos Roberto J. Soares, Douglas M. Miyamoto, Ricardo A. Katayama, Peterson L. Squair, Caio H.N. Barros &Ljubica Tasic
  6. Assessment of the safety and efficacy of poly-L-lactic acid for treatment of HIV-associated facial lipoatrophy. Cheryl M. Burges, MD; and Rafaela M. Quiroga, MD
  7. Injectable poly-L-lactic acid for cosmetic enhancement: Learning from the European experience. Kimberly Butterwick, MD and Nicholas J. Lowe, MD FRCP
  8. Reconstruction of injectable PDLLA, Efficacy of different diluents and a new accelerating method. Se-Yi Chen, MD; Szu-Ting Chen, PhD; Jui-Yu Lin, MD; Chuan-Yuan Lin, MD
  9. Antibacterial poly (D,L-lactic acid) coating of medical implants using a biodegradable drug delivery technology. Hans Gollwitzer, Karim Ibrahim, Henriette Meyer, Wolfram Mittelmeier, Raymonde Busch and Axel Steberger
  10. Działanie kwasu polimlekowego w tkankach w chirurgii estetycznej. Dorota Małgorzata Wydro
  11. Biodegradable poly(DL-lactide-coglycolide) microspheres. J.H. Eldridge, J.K. Staas, T.R. Tice and R.M. Gilley
  12. Poly(D,L-lactic acid) nanoparticle size reduction increases its immunotoxicity. Jessica Da Silva, Sandra Jesus, Natalia Bernardi, Mariana Colaco and Olga Borges
  13. RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin. Jie Xu, Ji-Hui Zhao, Ying Liu, Nian-ping Feng, Yong-Tai Zhang
  14. The use of polylactic acid to obtain biodegradable medical devices. R.Yu. Galimzyanova, MD Mevliyanova, D.R. Hisamieva N.V. Pesternnikova, I.N. Musin and M.S. Lisanevich
  15. Injectable fillers for volume replacement in the aging face. Timothy M. Greco, M.D., F.A.C.S.; Marcelo B. Antunes, M.D.; Seth A. Yellin, M.D.
  16. Soft Tissue augmentation using sculptra. Gail Humble, M.D. and Douglas Mest, M.D.
  17. Efficacy and safety of injection with poly-L-lactic acid compared with hyaluronic acid for correction of nasolabial fold: a randomized, evaluator-blinded, comperative study. M.Y. hyun, Y. Lee, Y.A. No, K.H. Yoo, M.N. Kim, C.K. Hong, S.E. Chang, C.H. Won and B.J. Kim
  18. Preparation and characterization of microporous poly(D,L-lactic acid) film for tissue engineering scaffold. Shuai Shi, Xiu Hong Wang, Gang Guo, Min Fan, Mei Juan Huang, Zhi Yong Qian,
  19. Contolled cisplatin delivery system using poly(D,L-lactic acid). O. Ike, Y. Shimizu, R. Wada, S.-H Hyon and Y. Ikada
  20. Sculptra: A stymulatory filler. Victor Lacombe, M.D.
  21. Injectable PLLA (Sculptra) technical considerations in soft-tissue contouring. Samuel M. Lam, M.D., Babak Azizzadeh, M.D., Miles Graivier, M.D.
  22. Degradation of poly(D,L-lactic acid) nanoparticles coated with albumin in model digestive fluids (USP XXII). F.B. Landry, D.V. Bazile, G. Spenlehauer, M. Veillard and J. Kreuter
  23. Internalization of poly(D,L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorber onto the particles. Jean_Christophe Leroux, Patricia Gravel, Lub Balant, Bernard Volet, Beatrice M. Anner, Eric Allemann, Eric Doelker and Robert Gurny.
  24. Biocompatibility of Poly_DL lactic acid (PDLLA) for lung tissue engineering. Y.M. Lin, A.R. Boccaccini, J.M. polak and A.E. Bishop
  25. Orofacial granulomas after injection of cosmetic fillers.Histopathologic and clinical study of 11 cases. T. Lombardii, J. Samson, F. Plantiere, C. Husson, R. Kuffer
  26. Long term (24-month) safety evaluation of PDLLA filler injection for the nasolabial fold. A multicenter, open, randomized, evaluator-blind, active-controlled design
  27. Optimizing poly-l-lactic acid use. Nick J. Lowe.
  28. The use of PDLLA devices for bone augmentation techniques: a systematic review. Marco Annunziata, Livia Nastri, Gennaro Cecoro and Luigi Guida
  29. Synthesis and characterization of low molecular weight polylactic acid. C.S. Proikakis, P.A. Tarantili and A.G. Andreopoulos
  30. Axonal regenration across an artificial scaffold combined with cel transplantation applied to the transected spinal cord. Mitsuhiro Enomoto, Madoka Ukegawa, Kazuyuki Fukushima, Kush Bhatt, Yoshiaki Wakabayashi, Atsushi Okawa
  31. Design of bioinspired polymeric materials based on poly (D,L-lactic acid) modifications toward improving its cytocompatibility. Xufeng Niu, Yanfeng Luo, Yonggang Li, Chunhua Fu, Jia Chen, Yuanliang Wang
  32. Biocompatibility and safety of PLA and its copolymers. Yuval Ramot, Moran Haim-Zada, Abraham J. Domb, Abraham Nyska
  33. Tamoxifen citrate-loaded poly(D,L) lactic acid nanoparticles: evaluation for their anticancer activity in vitro and in vivo. NR Ravikumara, Mausumi Bharadwaj and Basavaraj Madhusudhan.
  34. Poly-L-lactic acid: a new dimension in soft tissue augmentation. Adam M. Rotunda, Rhoda S. Narins
  35. A new option for volumetric restoration: poly-l-lactic acid. D Thioly-Bensoussan
  36. Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: an experimental pilot study. Ilka Uurto, MD’ Joonas Mikkonen, MSc; Jyrki Parkkinen, MD; Leo Keski-Nisula, MD; Timo Nevalainen, DVM, Minna Kellomaki, MSc; Pertti Tormala, MSc; and Juha-Pekka Salenius, MD
  37. Facial Volumetric Correction with injectable poly-L-lactic acid. Danny Vleggaar, MD
  38. The use of poly-L-lactic acid in the management of soft-tissue augmentation: a five-year experience. Didier Vochelle, MD
  39. Molecular biocompability evaluation of poly(D,L-lactic acid)-modified biomaterials based on long serial analysis of gene expression. Yan Xiang, Yuanliang Wang, Yanfeng Luo, Bingbing Zhang, Juan Xin, Danfang Zheng
  40. The structure and properties of biodegradable PLLA/PDLA for melt-blown nonwovens. Bin yu, Yongmin Cao, Hui Sun, Jian Han
  41. Compositions of injectable poly D,L-lactic acid and injectable poly-L-lactic acid. S.Y. Chen, J.Y. Lin, C.Y. Lin in C”linical and Experimental Dermatology”.
  42. Foreign body reaction to poly-D-L-lactic acid resobable plates used in craniofacial surgery. Nicholas Cen, BS; Matthew J. Davis, BS; Amjed Abu-Ghname, BS; Lesley W. Davies, PA-C, Kalyani R. Patel, MD and Edward P. Buchanan, MD in „The Journal of Craniofacial Surgery”


Collaborating manufacturer and supplier:


JUVELOOK is a time-active hybrid filler with a concentration of 42.5 mg of poly D,L lactide and 7.5 mg of non-cross-linked hyaluronic acid.

What makes Juvelook unique?

The only one in the world polylactic acid for use in the eye area, mesotherapy of the face, neck and neckline
Its ability to stimulate collagen production in the strongest way and restore youthful appearance in a gradual and natural way.
No need to massage the post-treatment areas due to the round shape of PDLLA acid molecules and its combination with non-cross-linked hyaluronic acid.
The durability of the treatment lasts over 24 months from the last treatment. The effect can be sustained by performing 1 reminder treatment after 24 months


Eye area: lower eyelid, crow’s feet, tear trough
Mesotherapy: face, neck, neckline

The effects of therapy
The effects of the therapy are visible immediately after injection. We obtain a filling effect thanks to the presence of hyaluronic acid. After about 2 weeks, the production of collagen is initiated by the presence of PDLLA lactic acid microparticles. The effects of the therapy last for over two years after the last treatment. The recommended number of treatments is 2 or 3, depending on the skin deficiency, at intervals of 8-12 weeks. After two years, we recommend performing 1 reminder treatment


Sculptra is a temporary facial injectable used to add volume to areas of the face and body to create a soft, natural, more youthful recontouring of the face.

Sculptra works by stimulating collagen production over a period of time, with results lasting for up to 2 years, however with annual upkeep, you can maintain excellent results for 5-10 years.

Collagen continues to build throughout treatment, meaning that your natural store of collagen is maintained – and even increased – even as you age and your store of collagen would otherwise naturally deplete.

Results are achieved by injecting Sculptra into targeted areas of the face to create an overall volumizing and rejuvenating effect. Sculptra can also be used to help contour the body.

  • Quick, 10-15-minute treatment
  • Performed by highly experienced Therapist
  • Longer lasting results than fillers, less maintenance required
  • Builds collagen organically
  • No downtime, and an immediate return to work and daily routine
  • Effective and natural – looking results
  • Conveniently located on Carr House Business Center, Bretherton

Sculptra can reduce fine lines and wrinkles and add volume in all areas of the face impacted by the ageing process. The overall effect is to deliver a refreshed, rejuvenated facial appearance.

Common areas for treatment include the upper, mid and lower face:

  • Cheeks
  • Chin 
  • Crow’s Feet
  • Forehead 
  • Jawline 
  • Mesolabial folds (mouth to chin lines)
  • Mouth 
  • Nasolabial folds (nose to mouth lines)
  • Temples 

Sculptra is made from poly-L-lactic acid (PLLA), a synthetic and biocompatible gel comprised of the same lactic acid that occurs naturally in the body – a very similar material to dissolvable stitches and soft tissue implants.

Once injected, it works to generate collagen production that is significant enough to fill out facial contours, grooves, and hollows, and add a lifted effect to cheeks.

Results are not immediate but are first visible around 6 weeks after treatment, and then continue to reveal themselves slowly for up to 2 years following treatment. This is an ideal treatment for anyone looking for a more youthful look that develops over time, with longer-lasting results and less frequent maintenance.

Sculptra treatment typically takes 15 – 20 minutes, and no longer than 30 minutes. You may need more than one session to deliver optimal results at the outset.

Results are not immediately following Sculptra treatment. Results should first start to be visible after about 6 weeks. Best results will be visible 6 months after treatment. The results of Sculptra last longer than alternative dermal filler treatment. Your results will last between 2 – 3 years, some time longer than dermal filler.

As with all injectable treatments you will be able to feel a little discomfort during Sculptra treatment as the injections are made.

Unlike surgical procedures, dermal fillers require no cuts, incisions or stitches to be made. Patients describe the sensation as feeling like a tiny scratch as the needle goes in, with a slight stinging sensation like the snap of an elastic band as the filler is applied.

For those feeling anxious, we can use a local anaesthetic to numb the area completely.

Price List

  • Lenisna - 1 Treatment £550.00

    (One x ampule 6ml)

  • Lenisna - 2 Treatments £990.00

    (Two x ampule 6ml)

(for best results it is recommended to have two sessions of LENISNA, 12 to 14 weeks apart)

Each subsequent treatment in the series benefits from a 10% 2 treatments discount – £110
  • Juvelook- 1 Treatment 190.00

    (One x ampule 2ml)

  • Juvelook - 2 Treatments 342.00

    (Two x ampule 2ml)

  • Juvelook - 3 Treatments 513.00

    (Three x ampule 2ml)

(for best results it is recommended to have two sessions of JUVELOOK, from 8 to 12 weeks apart)
Each subsequent treatment in the series benefits from a 10% 
2 treatments discount – £38
3 treatments discount – £57
  • Sculptra - 1 Treatment £450.00

    The initial treatment costs £450 and each treatment session there-after will cost £400. To achieve a good result a minimum of two sessions will be required at least 6 weeks apart. Many clients choose to have 3 – 4 sessions of treatment spread over 12 months, for optimal effect.

How Do I Prepare For Sculptra?

As with any treatment you will need to have a thorough consultation to decide if this treatment is right for you. However, unlike other botox and filler treatments it is not possible to have the Sculptra treatment at the same appointment as the consultation, as it must mixed at least 4 hours prior to administration.

Therefore although there is nothing special you need to do with your skin in preparation for your Sculptra treatment, we will always book your appointment in an afternoon session and ask you confirm your attendance on the day of the appointment, to prevent any wastage.

Ready to book your next treatment?

Use our online booking service...

Want to spread the cost? We have partnered with Payl8r to offer flexible repament plans. For more information click here.


Apply for finance